Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dabrafenib Mesylate

FDA-approved product (capsule, oral), marketed as Tafinlar.

Registered studies
24
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Dabrafenib Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Cutaneous melanoma
  • Glioma
  • Melanoma
  • Metastatic melanoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
B-raf serine-threonine kinase (braf) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA40.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

24registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dabrafenib Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dabrafenib Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy

    NCT02142036 · start 2014-05

    Registered record
    Registry ID
    NCT02142036
    Conditions
    Metastatic Cancer
    Interventions
    EMA-approved ATI based targeted therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-05
    Completion
    2018-08
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Cancer
    InterventionEMA-approved ATI based targeted therapy
    PhasePhase 2
    Registry statusCompleted

  • Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

    NCT02083354 · start 2014-03-18

    Registered record
    Registry ID
    NCT02083354
    Conditions
    Cancer; Melanoma
    Interventions
    Dabrafenib; Trametinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-03-18
    Completion
    2021-04-19
    Enrolment
    77

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer; Melanoma
    InterventionDabrafenib; Trametinib
    PhasePhase 2
    Registry statusCompleted

  • Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

    NCT01902173 · start 2013-10-08

    Registered record
    Registry ID
    NCT01902173
    Conditions
    Hematopoietic and Lymphoid Cell Neoplasm; Locally Advanced Malignant Solid Neoplasm; Locally Advanced Melanoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Stage IIIC Cutaneous Melanoma AJCC v7; Stage IV Cutaneous Melanoma AJCC v6 and v7; Unresectable Malignant Solid Neoplasm; Unresectable Melanoma
    Interventions
    Biopsy; Biospecimen Collection; Computed Tomography; Dabrafenib Mesylate; Magnetic Resonance Imaging; Trametinib Dimethyl Sulfoxide; Uprosertib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2013-10-08
    Completion
    2023-12-23
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematopoietic and Lymphoid Cell Neoplasm; Locally Advanced Malignant Solid Neoplasm; Locally Advanced Melanoma; Metastatic Malignant Solid Neoplasm +5 more
    InterventionBiopsy; Biospecimen Collection; Computed Tomography; Dabrafenib Mesylate +3 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

    NCT01947023 · start 2013-09-27

    Registered record
    Registry ID
    NCT01947023
    Conditions
    Metastatic Thyroid Gland Carcinoma; Unresectable Thyroid Gland Carcinoma
    Interventions
    Biopsy Procedure; Biospecimen Collection; Computed Tomography; Dabrafenib; Dabrafenib Mesylate; Echocardiography Test; Lapatinib; Lapatinib Ditosylate; Magnetic Resonance Imaging; Multigated Acquisition Scan; Positron Emission Tomography
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2013-09-27
    Completion
    2027-05-12
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Thyroid Gland Carcinoma; Unresectable Thyroid Gland Carcinoma
    InterventionBiopsy Procedure; Biospecimen Collection; Computed Tomography; Dabrafenib +7 more
    PhasePhase 1
    Registry statusActive not recruiting

  • A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors

    NCT01738451 · start 2013-01-22

    Registered record
    Registry ID
    NCT01738451
    Conditions
    Cancer
    Interventions
    GSK2118436 75 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-01-22
    Completion
    2014-11-28
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer
    InterventionGSK2118436 75 mg; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).

    NCT01682083 · start 2013-01-08

    Registered record
    Registry ID
    NCT01682083
    Conditions
    Melanoma
    Interventions
    Dabrafenib; Trametinib; Placebos
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-01-08
    Completion
    2023-07-31
    Enrolment
    870

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionDabrafenib; Trametinib; Placebos
    PhasePhase 3
    Registry statusCompleted

  • Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

    NCT01336634 · start 2011-08-05

    Registered record
    Registry ID
    NCT01336634
    Conditions
    Cancer
    Interventions
    Dabrafenib; Trametinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-08-05
    Completion
    2021-01-07
    Enrolment
    177

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer
    InterventionDabrafenib; Trametinib
    PhasePhase 2
    Registry statusCompleted

  • An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor

    NCT01231568 · start 2010-10-21

    Registered record
    Registry ID
    NCT01231568
    Conditions
    Cancer
    Interventions
    Regimen A; Regimen B; Regimen C; Regimen D
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-10-21
    Completion
    2011-05-13
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer
    InterventionRegimen A; Regimen B; Regimen C; Regimen D
    PhasePhase 1
    Registry statusCompleted

  • Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

    NCT02416232

    Registered record
    Registry ID
    NCT02416232
    Conditions
    Melanoma
    Interventions
    Trametinib; Dabrafenib
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    No longer available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma
    InterventionTrametinib; Dabrafenib
    PhaseNot recorded
    Registry statusNo longer available